Can immunotherapy let doctors dial down cancer treatment without sacrificing cures?
NCT ID NCT04988074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether giving the immunotherapy drug cemiplimab (sometimes with chemotherapy) before standard treatment can shrink tumors enough to allow less intense local therapy, such as reduced radiation or surgery. The goal is to maintain high cure rates while improving long-term quality of life, especially swallowing function. The study enrolls 32 people with advanced HPV-related head and neck cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab (a cancer immunotherapy drug, also known as Libtayo), sometimes combined with chemotherapy drugs carboplatin and paclitaxel
- What this could lead to
- If successful, this approach could allow some patients with advanced HPV-related head and neck cancer to receive less intense local treatments (like radiation or surgery), reducing side effects while still achieving high cure rates.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The immunotherapy may not shrink tumors enough to safely reduce treatment, and side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Experimental immune therapy aims to tackle HPV cancers before standard care
- Supercharged immune cells take on HPV cancers
- Could less radiation be just as effective for HPV throat cancer?
- Could a probiotic fight anal cancer in HIV patients?
- Experimental vaccines show promise against HPV-Driven cancers